Latest Conference Coverage

The administration of a subcutaneous 920-mg dose resulted in near-complete suppression of radiological and clinical disease activity as measured up to week 24, similar to the intravenous therapy.

Using a minimally invasive neuromodulation device, patients showed decreases in Overactive Bladder questionnaire symptoms and increases in OAB-q quality of life scores.

A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

The director of the MedStar Georgetown Headache Center gave commentary on the advances in the treatment of migraine, ways to better utilize CGRP medications, and the introduction of PACAP-targeting agents and their relevancy.

The director of headache medicine at The Mount Sinai Hospital talked about the often-overlooked realm of primary headaches beyond migraines as well as the importance of developing targeted treatments and increasing understanding of their pathophysiology. [WATCH TIME: 7 minutes]

The director of the Duke ALS Clinic at Duke Health discussed the advances in drug development for ALS and ways to evolve future trials to get optimal therapeutic benefit. [WATCH TIME: 3 minutes]

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well-tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

The associate professor of neurology at Icahn School of Medicine at Mount Sinai talked about the promising new treatments for multiple sclerosis, the significance of the spinal cord in the disease, and the use of artificial intelligence in neuroimaging. [WATCH TIME: 3 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth talked about recent studies presented at the International Headache Congress on a potential migraine prevention treatment targeting pituitary adenylate cyclase activating polypeptide. [WATCH TIME: 5 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed the Women in Neurology session she gave at IFN 2023, where women shared their experiences from their medical careers. [WATCH TIME: 3 minutes]

The associate professor of neurology at NYU Grossman School of Medicine discussed her talk at IFN 2023 on advancements in epilepsy treatments, highlighting new medications and surgical options. [WATCH TIME: 3 minutes]

Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.

The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]

The codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes]

The director of the Center for Brain Health and Alzheimer Prevention Clinic at Florida Atlantic University provided perspectives on the multimodal, multitargeted approach needed to treat Alzheimer disease. [WATCH TIME: 5 minutes]

The professor of neurology at Stony Brook University Medical Center discussed the progress observed in the field of multiple sclerosis and the lack of effective treatments for progressive forms of the disease. [WATCH TIME: 3 minutes]

The chief of the Movement Disorders Division at Mass General Hospital provided context on the goals behind the research careers reimagined course at the recently concluded ANA Annual Meeting.

The associate professor of neurology at Vanderbilt University Medical Center discussed the progress in stroke care, focusing on ischemic strokes and cerebral hemorrhages, and their connection with vascular diseases and cognitive disorders. [WATCH TIME: 3 minutes]

The associate professor of neurology at Yale School of Medicine discussed the differentiation of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein -associated disease from multiple sclerosis at IFN 2023. [WATCH TIME: 5 minutes]

The director of the Duke ALS Clinic at Duke Health provided perspective on the issues with getting newly approved ALS therapies to patients who need them the most. [WATCH TIME: 4 minutes]

Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.

The director of the MedStar Georgetown Headache Center provided insight on the excitement behind PACAP, how it may offer an alternate way of treating migraine, and where research behind it currently stands. [WATCH TIME: 4 minutes]

The associate professor at Washington University School of Medicine provided commentary on the state of care for pediatric stroke, and the challenges with identifying the most likely etiology. [WATCH 3 minutes]

The director of the Pediatric Epilepsy Center at UCSF provided perspective on the advances in the treatment of Dravet syndrome, emerging research concepts in the field, and the influence of genetic testing. [WATCH TIME: 5 minutes]

The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.

The associate professor at Washington University School of Medicine discussed the reasons for why some institutions have different risk benefit analyses for thrombolysis, and whether this causes challenges for the healthcare system. [WATCH TIME: 4 minutes]

The director of the Pediatric Epilepsy Center at UCSF provided perspective on STK-001, a promising antisense oligonucleotide in development, and the shift in how Dravet syndrome is discussed and managed.